This product is a recombinant Mouse antibody that can recognize Pan-ebolavirus. 6D6 binds to the conserved glycoprotein fusion peptide, implicating it as a site of immune vulnerability that could be exploited to reliably elicit a pan-ebolavirus neutralizing antibody response.
Figure 1 Neutralizing properties of MAb 6D6 against ebolaviruses.
(a) VSV pseudotyped with the indicated GPs or (b) infectious EBOV, SUDV, TAFV, BDBV, RESTV, and MARV were incubated with purifed MAb 6D6 followed by inoculation into confluent Vero E6 cells. (c) Binding activities of MAbs 6D6 (red), ZGP133/3.16 (orange) and ZGP226/8.1 (blue) were examined by ELISA using EBOV GP as the antigen. (d) Neutralizing activities of MAbs 6D6 (red), ZGP133/3.16 (orange), and ZGP226/8.1 (blue) against VSV pseudotyped with EBOV GP are shown.
Furuyama, W., Marzi, A., Nanbo, A., Haddock, E., Maruyama, J., Miyamoto, H., ... & Takada, A. (2016). Discovery of an antibody for pan-ebolavirus therapy. Scientific reports, 6, 20514.
Figure 2 Neutralization of pseudotyped viruses by the selected antibody cocktails.
Neutralization of pseudotyped viruses by the selected antibody cocktails: EBOV Mayinga (A), EBOV Makona (B), BDBV (C), and SUDV (D). Each data point represents an average of duplicates ± SD. Experiments were repeated at least three times.
Rijal, P., Elias, S. C., Machado, S. R., Xiao, J., Schimanski, L., O’Dowd, V., ... & Jin, J. (2019). Therapeutic monoclonal antibodies for Ebola virus infection derived from vaccinated humans. Cell reports, 27(1), 172-186.
Figure 3 Protective efcacy of MAb 6D6 in mice.
(a) BALB/c mice were intraperitoneally infected with a lethal dose of mouse-adapted EBOV. (b) IFNAR−/− mice were intraperitoneally infected with EBOV1976 (upper panels) or SUDV (bottom panels). Twenty-four hours afer infection, animals were treated intraperitoneally with either 100μg of MAb 6D6 or a vehicle control (PBS). The animals were then monitored for 14 days for clinical signs of infection and weighed daily. Body weight (lef panels) and survival curves (right panels) are shown.
Furuyama, W., Marzi, A., Nanbo, A., Haddock, E., Maruyama, J., Miyamoto, H., ... & Takada, A. (2016). Discovery of an antibody for pan-ebolavirus therapy. Scientific reports, 6, 20514.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
PFBC-374 | Recombinant Mouse Anti-Pan-ebolavirus Antibody Fab Fragment (6D6) | ELISA, Neut | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
PSBC-374 | Recombinant Mouse Anti-Pan-ebolavirus Antibody scFv Fragment (6D6) | ELISA, Neut | Mouse scFv |
There are currently no Customer reviews or questions for PABC-374. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.